Everolimus/methylprednisolone

Everolimus/methylprednisolone Reactions 1680, p135 - 2 Dec 2017 Eventually, the patient developed hypertriglyceridaemia and proteinuria due to the everolimus therapy. The proteinuria was manageable. The everolimus therapy was continued along with methylprednisolone. However, after 5 months of the Various toxicities: 9 case reports transplantation, the patient died due to relapse of chronic In a retrospective and observational pilot study myeloid leukaemia. (CMUH105-REC2-145), 9 patients [ not all sexes stated ] aged Patient 10: The 15-year-old boy had myelodysplastic between 1.1-19 years, were described, who developed syndrome. He underwent allogeneic haematopoietic stem cell hypertriglyceridaemia (5 patients) or thrombotic transplantation. However, he developed acute graft versus microangiopathy, hypertriglyceridaemia and proteinuria host disease despite prophylaxis therapy. He received therapy (1 patient) or hypertriglyceridaemia and proteinuria with oral everolimus with an initial dose of 1.6 mg/m2/day in (3 patients) following the therapy with everolimus; one of two divided doses and methylprednisolone 2 mg/Kg/day for these 9 patients (a 15-year-old boy; patient 10) additionally acute graft versus host disease. After four months of developed CNS aspergillosis due to methylprednisolone [not everolimus initiation, he developed thrombotic all routes, duration of therapy to reaction onsets and outcomes microangiopathy. His platelet count decreased along with stated]. abnormally elevated schistocyte levels. He also developed Patient 2: The 14-year-old patient had acute lymphoblastic hypertriglyceridaemia and proteinuria due to the everolimus leukaemia. The patient underwent allogeneic haematopoietic therapy. Hence, the boy’s everolimus therapy was replaced stem cell transplantation. However, the patient developed with mycophenolate mofetil. Consequently, his thrombotic acute graft versus host disease despite prophylaxis therapy. microangiopathy resolved. However, at 2 months following The patient received therapy with oral everolimus with an the discontinuation of everolimus, he developed CNS initial dose of 1.6 mg/m /day in two divided doses and aspergillosis due to the methylprednisolone therapy. Other methylprednisolone for acute graft versus host toxicities except hypertriglyceridaemia were manageable. disease.Eventually, the patient developed Patient 11: The 18.3-year-old patient had acute hypertriglyceridaemia due to the everolimus therapy. The lymphoblastic leukaemia. The patient underwent allogeneic everolimus therapy was continued along with haematopoietic stem cell transplantation. However, the methylprednisolone. patient developed acute graft versus host disease despite Patient 4: The 15-year-old patient had acute myeloid prophylaxis therapy. The patient received therapy with oral leukaemia. The patient underwent allogeneic haematopoietic everolimus with an initial dose of 1.6 mg/m2/day in two stem cell transplantation. However, the patient developed divided doses and methylprednisolone for acute graft versus acute graft versus host disease despite prophylaxis therapy. host disease. Eventually, the patient developed The patient received therapy with oral everolimus with an hypertriglyceridaemia and proteinuria due to the everolimus initial dose of 1.6 mg/m2/day in two divided doses and therapy. The everolimus therapy was continued along with methylprednisolone for acute graft versus host disease. methylprednisolone. However, after 3 months of the Eventually, the patient developed hypertriglyceridaemia and transplantation, the patient died due to relapse of acute proteinuria due to the everolimus therapy. The proteinuria was lymphoblastic leukaemia. manageable. The everolimus therapy was continued along Patient 12: The 16.4-year-old patient had acute myeloid with methylprednisolone. leukaemia. The patient underwent allogeneic haematopoietic Patient 5: The 19-year-old patient had acute myeloid stem cell transplantation. However, the patient developed leukaemia. The patient underwent allogeneic haematopoietic acute graft versus host disease despite prophylaxis therapy. stem cell transplantation. However, the patient developed The patient received therapy with oral everolimus with an acute graft versus host disease despite prophylaxis therapy. initial dose of 1.6 mg/m2/day in two divided doses and The patient received therapy with oral everolimus with an methylprednisolone for acute graft versus host disease. initial dose of 1.6 mg/m2/day in two divided doses and Eventually, the patient developed hypertriglyceridaemia due to methylprednisolone for acute graft versus host disease. the everolimus therapy. The everolimus therapy was Eventually, the patient developed hypertriglyceridaemia due to continued along with methylprednisolone. the everolimus therapy. The everolimus therapy was Author comment: "The most common complication continued along with methylprednisolone. probably associated with everolimus in the present study was Patient 6: The 6.4-year-old patient had myelodysplastic hypertriglyceridemia (69.2%), and these patients were syndrome. The patient underwent allogeneic haematopoietic asymptomatic without treatment interruption." "(H)e stem cell transplantation. However, the patient developed developed CNS aspergillosis and prolonged use of steroids acute graft versus host disease despite prophylaxis therapy. may be an important contributing factor." "Thrombotic The patient received therapy with oral everolimus with an microangiopathy was rare (7.7%), but can be quickly solved initial dose of 1.6 mg/m2/day in two divided doses and by stopping everolimus and [ciclosporin] treatment." "Other methylprednisolone for acute graft versus host disease. toxicities were manageable." Eventually, the patient developed hypertriglyceridaemia due to the everolimus therapy. The everolimus therapy was Chao YH, et al. Everolimus for pediatric patients with acute graft-versus-host continued along with methylprednisolone. disease after hematopoietic stem cell transplantation: A pilot study. Medicine 96: e8464, No. 44, Nov 2017. Available from: URL: http://doi.org/10.1097/ Patient 7: The 1.1-year-old patient had severe aplastic MD.0000000000008464 - Taiwan 803284322 anaemia. The patient underwent allogeneic haematopoietic stem cell transplantation. However, the patient developed acute graft versus host disease despite prophylaxis therapy. The patient received therapy with oral everolimus with an initial dose of 1.6 mg/m2/day in two divided doses and methylprednisolone. Eventually, the patient developed hypertriglyceridaemia due to the everolimus therapy. The everolimus therapy was continued along with methylprednisolone. Patient 9: The 16.8-year-old patient had chronic myeloid leukaemia. The patient underwent allogeneic haematopoietic stem cell transplantation. However, the patient developed acute graft versus host disease despite prophylaxis therapy. The patient received therapy with oral everolimus with an initial dose of 1.6 mg/m2/day in two divided doses and methylprednisolone for acute graft versus host disease. 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Everolimus/methylprednisolone

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/everolimus-methylprednisolone-ZpVdbU1Kai
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39066-5
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial